Clinical Trial Update: Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation [Phase 1]

View source ↗

Summary

ClinicalTrials.gov entry indicates withdrawal of a Phase Ib study of furmonertinib in non-small cell lung cancer with EGFR exon 20 insertion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: NSCLC | Phase 1 | Status: WITHDRAWN